Skip to main content

Table 2 Effect of prescription doses of phosphate binders and ESA after 5 months of observation

From: Comparative analysis of the phosphate-binding effects of sucroferric oxyhydroxide, ferric citrate, and lanthanum carbonate

   Mean SD SE ANOVA 95% CI Minimum Maximum
       Lower limit Upper limit   
Total amount of prescription dose (per 5 months) FC 142.9 80.2 8.0 * 127.0 158.7 10.5 437.8
SF 132.1 84.0 9.3 * 113.6 150.5 5.3 399.0
LC 208.7 89.9 8.0 * 192.8 224.5 35.0 462.0
  Total 166.8 91.9 5.2   156.5 177.1 5.3 462.0
Total prescription dose/starting dose FC 0.6 0.4 0.0 * 0.6 0.7 0.0 2.0
SF 1.1 0.7 0.1 * 1.0 1.3 0.0 3.4
LC 1.8 0.8 0.1 * 1.7 1.9 0.3 4.0
  Total 1.2 0.8 0.0   1.2 1.3 0.0 4.0
Phosphate change rate (%) [(Pi_end − Pi_week_0) × 100/Pi_week_0] FC 2.9 31.5 3.1   −3.4 9.1 −45.1 116.3
SF −10.8 22.6 2.5 * −15.8 −5.9 −54.0 48.8
LC −3.2 27.8 2.5   −8.1 1.7 −59.5 152.4
  Total −3.3 28.3 1.6   −6.4 −0.1 −59.5 152.4
Number of times ferritin ≥300 ng/mL FC 0.1 0.4 0.0   0.0 0.2 0.0 4.0
SF 2.3 1.5 0.2 * 1.9 2.6 0.0 5.0
LC 0.0 0.2 0.0   0.0 0.1 0.0 2.0
  Total 0.6 1.3 0.1   0.5 0.8 0.0 5.0
Total amount of ESA dose (μg) # FC 440.0 567.6 56.5   327.9 552.0 0.0 3960.0
SF 265.7 339.2 37.5 * 191.2 340.2 0.0 1880.0
LC 424.7 445.4 39.7   346.2 503.2 0.0 2640.0
  Total 387.5 469.9 26.7   334.9 440.1 0.0 3960.0
  1. Total amount of ESA dose was calculated using an epoetin:darbepoetin:CERA conversion ratio of 200:1:1
  2. SD standard deviation, SE standard error
  3. *used as indicators for p values